GYRE THERAPEUTICS, INC. - COM (GYRE)

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / COM
Number of holders
19
Total 13F shares, excl. options
816,435
Shares change
+208,942
Total reported value, excl. options
$14,271,940
Value change
+$3,343,587
Number of buys
13
Number of sells
-8
Price
$17.48

Significant Holders of GYRE THERAPEUTICS, INC. - COM (GYRE) as of Q1 2024

24 filings reported holding GYRE - GYRE THERAPEUTICS, INC. - COM as of Q1 2024.
GYRE THERAPEUTICS, INC. - COM (GYRE) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 816,435 shares .
Largest 10 shareholders include VANGUARD GROUP INC (195,098 shares), BlackRock Inc. (171,802 shares), GEODE CAPITAL MANAGEMENT, LLC (160,589 shares), MILLENNIUM MANAGEMENT LLC (60,319 shares), GOLDMAN SACHS GROUP INC (46,093 shares), STATE STREET CORP (40,538 shares), JANE STREET GROUP, LLC (30,555 shares), MARSHALL WACE, LLP (25,544 shares), NORTHERN TRUST CORP (24,068 shares), and JPMORGAN CHASE & CO (20,028 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.